open access
An approach to develop personalized radiopharmaceuticals by modifying 2-[18F]fluoro-2-deoxy-D-glucose (2-[18F]FDG)
, 2
Affiliations- Clinic Nuclear Medicine, UMHAT “St. Marina”, Medical University, Varna, Bulgaria
- Department of Analytical Chemistry, Faculty of Chemistry and Pharmacy, Sofia University, Bulgaria
open access
Abstract
Background: A challenge for modern medicine is the development of clinical protocols for precise diagnosis and therapy. This study aimed to propose a simple method for modification of 2-[18F]FDG used routinely in hospitals in a way, appropriate for patients’ personalized radiopharmaceuticals approach.
Material and methods: For the purposes of the presented study chemo selective method for indirect radiofluorination was applauded to custom synthesized aminooxy- and hydrazine-functionalized tetrazines for 18F-glycolation via oxime or hydrazone formation. 2-[18F]FDG produced with medical baby cyclotron in Nuclear Medicine Clinic at the University Hospital St. Marina-Varna, was used. Thin layer chromatography (TLC) and radio TLC were used to follow the progress of synthesis and to determine radio chemical yield (RCY).
Results: The 2-[18F]FDG was modified with two bifunctional tetrazines aminooxy-acetic acid-6-(2-aminooxy-acetoxy)-[1,2,4,5] tetrazin-3-yl ester (Tz1) and {3-[4-(6-phenyl-[1,2,4,5]tetrazin-3-yl)-phenoxy]-propyl}-hydrazine (Tz2) via oxime and hydrazone formation. The radiolabeling was carried out as one-pot reaction with following parameters: temperature 70–75°C; catalyst p- diaminobenzene (Cat.); pH = 4.2; time 30 minutes; RCY = 70–99%. The radiolabeled tetrazines are appropriate for further bioorthogonal (pretargeting) strategy by click reactions with trans-cyclooctene conjugated bioactive molecules. The methodology is applicable to standard clinical conditions.
Abstract
Background: A challenge for modern medicine is the development of clinical protocols for precise diagnosis and therapy. This study aimed to propose a simple method for modification of 2-[18F]FDG used routinely in hospitals in a way, appropriate for patients’ personalized radiopharmaceuticals approach.
Material and methods: For the purposes of the presented study chemo selective method for indirect radiofluorination was applauded to custom synthesized aminooxy- and hydrazine-functionalized tetrazines for 18F-glycolation via oxime or hydrazone formation. 2-[18F]FDG produced with medical baby cyclotron in Nuclear Medicine Clinic at the University Hospital St. Marina-Varna, was used. Thin layer chromatography (TLC) and radio TLC were used to follow the progress of synthesis and to determine radio chemical yield (RCY).
Results: The 2-[18F]FDG was modified with two bifunctional tetrazines aminooxy-acetic acid-6-(2-aminooxy-acetoxy)-[1,2,4,5] tetrazin-3-yl ester (Tz1) and {3-[4-(6-phenyl-[1,2,4,5]tetrazin-3-yl)-phenoxy]-propyl}-hydrazine (Tz2) via oxime and hydrazone formation. The radiolabeling was carried out as one-pot reaction with following parameters: temperature 70–75°C; catalyst p- diaminobenzene (Cat.); pH = 4.2; time 30 minutes; RCY = 70–99%. The radiolabeled tetrazines are appropriate for further bioorthogonal (pretargeting) strategy by click reactions with trans-cyclooctene conjugated bioactive molecules. The methodology is applicable to standard clinical conditions.
Keywords
2-[18F]FDG; bifunctional compounds; tetrazine; hydrazone and oxime formation; personal medicine
About this articleTitle
An approach to develop personalized radiopharmaceuticals by modifying 2-[18F]fluoro-2-deoxy-D-glucose (2-[18F]FDG)
Journal
Issue
Vol 26 (2023): Continuous Publishing
Article type
Research paper
Pages
109-115
Published online
2023-10-03
Page views
463
Article views/downloads
264
DOI
Pubmed
Bibliographic record
Nucl. Med. Rev 2023;26:109-115.
Keywords
2-[18F]FDG
bifunctional compounds
tetrazine
hydrazone and oxime formation
personal medicine
Authors
Gergana Simeonova
Boyan Todorov
References (32)- Hossain F., Synthesis of glycopeptides for evaluation in cancer cells. (PhD dissertation) The University of Toledo, 2019. https://etd.ohiolink.edu/apexprod/rws_etd/send_file/send?accession=toledo157477493528402&disposition=inline (26.01.2023).
- Petriev VM, Tishchenko VK, Krasikova RN. 18F-FDG and other labeled glucose derivatives for use in radionuclide diagnosis of oncological diseases (review). Pharm Chem J. 2016; 50(4): 209–220.
- Carberry P, Lieberman BP, Ploessl K, et al. New F-18 prosthetic group via oxime coupling. Bioconjug Chem. 2011; 22(4): 642–653.
- Choi JiY, Lee BC. Click reaction: an applicable radiolabeling method for molecular imaging. Nucl Med Mol Imaging. 2015; 49(4): 258–267.
- Valdivia AO, López JL, Vargas-Rodríguez Y, et al. Producción de radiofármacos para tomografía por emisión de positrones (PET) y su aplicación en el diagnóstico de diversas enfermedades. Educ Quimica. 2016; 27(4): 292–299.
- Maschauer S, Prante O. A series of 2-O-trifluoromethylsulfonyl-D-mannopyranosides as precursors for concomitant 18F-labeling and glycosylation by click chemistry. Carbohydr Res. 2009; 344(6): 753–761.
- Zeglis BM, Sevak KK, Reiner T, et al. A pretargeted PET imaging strategy based on bioorthogonal Diels-Alder click chemistry. J Nucl Med. 2013; 54(8): 1389–1396.
- Davis RA, Hausner SH, Sutcliffe JL. Peptides as radiopharmaceutical vectors. In: Lewis J, Windhorst A, Zeglis B. ed. Radiopharmaceutical Chemistry. Springer Nature Switzerland AG 2019: 137–162.
- García-Vázquez R, Battisti UM, Herth MM. Recent advances in the development of tetrazine ligation tools for pretargeted nuclear imaging. Pharmaceuticals (Basel). 2022; 15(6).
- Knight JC, Cornelissen B. Bioorthogonal chemistry: implications for pretargeted nuclear (PET/SPECT) imaging and therapy. Am J Nucl Med Mol Imaging. 2014; 4(2): 96–113.
- Reiner T, Zeglis BM. The inverse electron demand Diels-Alder click reaction in radiochemistry. J Labelled Comp Radiopharm. 2014; 57(4): 285–290.
- van de Watering FCJ, Rijpkema M, Robillard M, et al. Pretargeted imaging and radioimmunotherapy of cancer using antibodies and bioorthogonal chemistry. Front Med (Lausanne). 2014; 1: 44.
- Oliveira BL, Guo Z, Bernardes GJL. Inverse electron demand Diels-Alder reactions in chemical biology. Chem Soc Rev. 2017; 46(16): 4895–4950.
- García-Vázquez R, Jørgensen JT, Bratteby KE, et al. Development of 18F-labeled bispyridyl tetrazines for in vivo pretargeted PET imaging. Pharmaceuticals (Basel). 2022; 15(2): 245.
- Schirrmacher R, Wängler B, Bailey J, et al. Small prosthetic groups in 18F-radiochemistry: useful auxiliaries for the design of 18F-PET tracers. Semin Nucl Med. 2017; 47(5): 474–492.
- van der Born D, Pees A, Poot AJ, et al. Fluorine-18 labelled building blocks for PET tracer synthesis. Chem Soc Rev. 2017; 46(15): 4709–4773.
- Keinänen O, Partelová D, Alanen O, et al. Efficient cartridge purification for producing high molar activity [F]fluoro-glycoconjugates via oxime formation. Nucl Med Biol. 2018; 67: 27–35.
- Kim DH, Choe YS, Jung KH, et al. A (18)F-labeled glucose analog: synthesis using a click labeling method and in vitro evaluation. Arch Pharm Res. 2008; 31(5): 587–593.
- Wuest F, Hultsch C, Berndt M, et al. Direct labelling of peptides with 2-[18F]fluoro-2-deoxy-d-glucose ([18F]FDG). Bioorg Med Chem Lett. 2009; 19(18): 5426–5428.
- Maschauer S, Prante O. Sweetening Pharmaceutical Radiochemistry by18F-Fluoroglycosylation: A Short Review. BioMed Research International. 2014; 2014: 1–16.
- Bouvet VR, Wuest F. Application of [18F]FDG in radiolabeling reactions using microfluidic technology. Lab Chip. 2013; 13(22): 4290–4294.
- Richter S, Wuest F. 18F-Labeled peptides: the future is bright. Molecules. 2014; 19(12): 20536–20556.
- Knight JC, Cornelissen B. Click Chemistry in Radiopharmaceutical Chemistry. In: Lewis JS, Windhors AD, Zeglis BM. ed. Radiopharmaceutical Chemistry. Springer Nature Switzerland AG, Switzerland 2019: 467–479.
- Ulrich S, Boturyn D, Marra A, et al. Oxime ligation: a chemoselective click-type reaction for accessing multifunctional biomolecular constructs. Chemistry. 2014; 20(1): 34–41.
- Namavari M, Padilla De Jesus O, Cheng Z, et al. Direct site-specific radiolabeling of an Affibody protein with 4-[18F]fluorobenzaldehyde via oxime chemistry. Mol Imaging Biol. 2008; 10(4): 177–181.
- Keinänen O, Fung K, Pourat J, et al. Pretargeting of internalizing trastuzumab and cetuximab with a F-tetrazine tracer in xenograft models. EJNMMI Res. 2017; 7(1): 95.
- Simeonova G, Todorov B, Lyubomirova V. Modification of 18F-fluorodesoxy-glucose (18F-FDG) radiopharmaceutical by oxime conjugation. RAP Conference Proceedings. 2021; 6: 11–15.
- Kettenbach K, Schieferstein H, Ross TL. 18F-labeling using click cycloadditions. Biomed Res Int. 2014; 2014: 361329.
- Rashidian M, Keliher E, Dougan M, et al. Use of 18F-2-Fluorodeoxyglucose to Label Antibody Fragments for Immuno-Positron Emission Tomography of Pancreatic Cancer. ACS Cent Sci. 2015; 1(3): 142–147.
- Carberry P, Carpenter AP, Kung HF. Fluoride-18 radiolabeling of peptides bearing an aminooxy functional group to a prosthetic ligand via an oxime bond. Bioorg Med Chem Lett. 2011; 21(23): 6992–6995.
- Kölmel DK, Kool ET. Oximes and hydrazones in bioconjugation: mechanism and catalysis. Chem Rev. 2017; 117(15): 10358–10376.
- Li XG, Helariutta K, Roivainen A, et al. Using 5-deoxy-5-[18F]fluororibose to glycosylate peptides for positron emission tomography. Nat Protoc. 2014; 9(1): 138–145.
